Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 11INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 44Biopsy 35Specimen Handling 34Magnetic Resonance Spectroscopy 30fludarabine 27aldesleukin 26Filgrastim 20Carboplatin 20Paclitaxel 19fludarabine phosphate 17Rituximab 17Sirolimus 16Cisplatin 16Temozolomide 15Radiotherapy 14Etoposide 14Bevacizumab 14Prednisone 13Gemcitabine 13Docetaxel 13Cytarabine 13Erlotinib Hydrochloride 12Fluorouracil 11Vorinostat 10Vincristine 10Sorafenib 10Electrocardiography 10Doxorubicin 10temsirolimus 9pembrolizumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × NIH × Metformin × Clear all
NCT02495103 2021-01-26

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
7 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡